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Detection of KPC-2 in a Clinical Isolate of Proteus mirabilis and First
Reported Description of Carbapenemase Resistance Caused by a
KPC -Lactamase in P. mirabilis
R. Tibbetts,1† J. G. Frye,2 J. Marschall,3 D. Warren,3 and W. Dunne1*
Department of Pathology and Immunology, Division of Laboratory Medicine, Washington University School of Medicine, St. Louis,
Missouri 631101; Bacterial Epidemiology and Antimicrobial Resistance Research Unit, USDA, Agricultural Research Service,
Athens, Georgia 306052; and Division of Infectious Diseases, Washington University School of Medicine, St. Louis, Missouri3
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An isolate of Proteus mirabilis recovered from blood cultures of a diabetic patient was shown to be resistant
to imipenem, meropenem, and ertapenem by disk diffusion susceptibility testing. Amplification of whole-cell
and/or plasmid DNA recovered from the isolate with primers specific for the blaKPC carbapenemase gene
produced an amplicon of the expected size which was confirmed to be blaKPC-2 by sequence analysis. Trans-
formation of a susceptible Escherichia coli host with plasmid preparations from the isolate generated a
transformant for which the MICs of all of the carbapenems tested were increased three- to fourfold. We believe
this to be the first report of carbapenem resistance in P. mirabilis caused by the acquisition of blaKPC.
blaKPC-mediated carbapenem resistance among gram-nega-
tive bacteria is a relatively recent and emerging concern among
health care practitioners in the United States. Chiefly limited
to isolates of Klebsiella pneumoniae in initial surveillance re-
ports (3–5), this carbapenem-hydrolyzing molecular class A
-lactamase has since been identified in a variety of Entero-
bacteriaceae including Escherichia coli (12), Enterobacter spp.
(3, 7), Citrobacter spp.(7), Salmonella spp. (11), and Serratia
marcescens (7), as well as Pseudomonas aeruginosa (16). The
continued transfer of blaKPC between bacterial genera presents
a serious challenge to infection prevention and control person-
nel because the enzyme mediates resistance not only to car-
bapenems but to all -lactam antimicrobial agents, including
cephalosporins, cephamycins, penicillins, and monobactams
(13). Further, infection with blaKPC-producing bacteria is as-
sociated with higher patient mortality rates (4). Like many
members of the family Enterobacteriaceae, Proteus spp. can
harbor numerous plasmid- and integron-mediated antimicro-
bial resistance determinants (8, 9). Carbapenem resistance
among Proteus spp. has previously been shown to be mediated
by the OXA-23 molecular class D -lactamase (2) or through
porin mutation with or without decreased expression of peni-
cillin binding proteins (15). Recently, Tsakris et al. (14) re-
ported on the first isolate of P. mirabilis producing a VIM-1
molecular class B metallo--lactamase resulting in carbap-
enem resistance. Herein, we give what is believed to be the first
report of a carbapenem-resistant isolate of P. mirabilis possess-
ing a transmissible plasmid-mediated blaKPC-2 gene.
(This work was presented in part at the European Confer-
ence of Clinical Microbiology and Infectious Disease, Munich,
Germany, 2007.)
The isolate of interest was presumptively identified as P.
mirabilis on the basis of Gram staining, swarming motility on
blood agar plates, inability to ferment lactose, and production
of hydrogen sulfide, oxidase, and indole reactions, as well as
phenotypic identification with the Vitek-2 identification system
(bioMe´rieux, Marcy l’Etoile, France). Confirmation of the
identification was accomplished by extended microbiological
and biochemical techniques performed by the Missouri De-
partment of Health Laboratory (Jefferson City). Antimicrobial
susceptibility testing was performed by disk diffusion according
to CLSI guidelines (6). In addition, MICs of ertapenem, mero-
penem, imipenem, and doripenem were determined with the
Etest (AB Biodisk, Solna, Sweden). Inhibition of blaKPC activ-
ity was evaluated by disk approximation analysis as described
previously (1).
Plasmid isolation, PCR, transformation, and restriction di-
gestion. Total plasmid DNA was extracted from overnight cul-
tures of the study isolate, the Top 10 E. coli host strain (TT),
and selected transformants with the Qiagen plasmid mini
extraction kit according to the manufacturer’s procedures
(Qiagen, Hilden, Germany). The presence of blaKPC was de-
termined by conventional PCR with primers specific for blaKPC
as described previously (5). Transformants were selected on
nutrient agar plates containing 4 g/ml imipenem. PCR-gen-
erated fragments were cloned into pCR-II and transformed
into a chemically competent TT host according to the manu-
facturer’s protocols (Qiagen). Transformants were selected on
nutrient agar plates with 100 g/ml ampicillin and screened by
conventional PCR as described above.
DNA sequencing and analysis. Sequencing of the blaKPC
PCR product cloned into pCR-II (TT/pPmir) was performed
with primers F (5-ATGTCACTGTATCGCCGTC-3) and R
(5-CTCAGTGCTCTACAGAAAACC-3) as described previ-
ously (16), with BigDye Terminator cycle sequencing kit v3.1
(Applied Biosystems, Inc., Foster City, CA) and an MJ Re-
* Corresponding author. Mailing address: Department of Pathology
and Immunology, Division of Laboratory Medicine, Washington Uni-
versity School of Medicine, St. Louis, MO 63122. Phone: (314) 362-
1547. Fax: (314) 362-1461. E-mail: dunne@wustl.edu.
† Present address: Department of Pathology, Henry Ford Health
System, 2799 West Grand Blvd., Detroit, MI 48202.
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search PTC-200 DNA Engine thermal cycler (Bio-Rad Labo-
ratories, Waltham, MA). Sequencing reaction mixtures were
purified by ethanol precipitation, separated, and analyzed with
an ABI PRISM 3100 genetic analyzer (ABI, Foster City, CA)
by following the manufacturer’s protocols. Forward and re-
verse strands of two independent PCR products were each
sequenced. Sequences were aligned and compared to pub-
lished sequences of the blaKPC-2 gene with Vector NTI v10.3.0
software (Invitrogen, Carlsbad, CA).
The study isolate was recovered from one of three cultures
of blood drawn from a 53-year-old patient with uncontrolled
diabetes mellitus. The patient was noncompliant with diabetes
management and had recently undergone bilateral amputation
of the lower extremities for gangrene. Prior antimicrobial
therapy included vancomycin, cefepime, metronidazole, cip-
rofloxacin, and clindamycin. However, the patient had not
been previously treated with a carbapenem. Disk diffusion
testing indicated that the organism was resistant to imi-
penem, ampicillin, and cefazolin. Additional analysis with
the Vitek2 automated system indicated that this organism
was resistant to ampicillin, piperacillin, cefazolin, cefuroxime,
and ceftriaxone; intermediately resistant to cefepime; and sus-
ceptible to piperacillin-tazobactam and ciprofloxacin. Because
our laboratory was currently performing a prospective analysis
of all carbapenem-resistant Enterobacteriaceae, the isolate was
further tested for the presence of the blaKPC gene with con-
ventional PCR assays. The patient was subsequently placed on
piperacillin-tazobactam, followed by ciprofloxacin, and subse-
quent blood cultures were negative.
A single large plasmid (pPmir) was recovered from the study
isolate (data not shown). Conventional and real-time (data not
shown) PCR analyses of this plasmid, as well as total DNA,
were positive for the presence of the blaKPC gene. Additional
antimicrobial susceptibility testing with E-strips demonstrated
that the MICs of doripenem, meropenem, imipenem, and er-
tapenem were 32 g/ml (Table 1). Following transformation
of the TT host strain, a single colony resistant to 4 g/ml
imipenem was selected and subcultured. As indicated in Fig. 1,
a fragment of the size expected was generated from the trans-
formant but not from the TT host strain. MIC testing of the
transformant indicated that there was a three- to fourfold
increase in the MICs of doripenem, meropenem, imipenem,
and ertapenem compared to those for the susceptible host
strain (Table 1). In addition, disk approximation analysis indi-
cated an inhibition of blaKPC in the presence of clavulanate
(data not shown).
Isolated pPmir and TT/pPmir were submitted for sequence
analysis with primers specific for blaKPC. A subsequent BLAST
search showed that the amplified fragments were 100% homol-
ogous at the nucleic acid level (Fig. 2) and 100% identical at
the amino acid level (Fig. 3) to the blaKPC-2 gene submitted to
GenBank (accession no. AAK70220).
In this report, we describe what we believe to be the first
reported case of infection caused by a strain of carbapenem-
resistant Proteus mirabilis positive for the blaKPC-2 gene. While
this finding is not totally unexpected, given the recent docu-
mented spread of blaKPC carbapenemase to a number of gen-
era within the family Enterobacteriaceae (3–5, 11, 12), it is a
disturbing trend, given the relatively recent discovery of this
family of -lactamases. While extended-spectrum -lactamase
and carbapenemase activities have previously been docu-
mented in Proteus species (2, 10, 14, 15, 17), the addition of
blaKPC to the spectrum of resistance factors carried by an
organism that traditionally has been placed in the low-level
endogenous resistance category (similar to Klebsiella spp.) is
equally troubling. It is possible that, as part of the normal gut
flora, Proteus species may be unrecognized vectors for the
dissemination of blaKPC until, as in our case, they are identified
as a clinically significant cause of infection. As a case in point,
until recently, KPC-positive K. pneumoniae recovered from
urine might have gone unrecognized in our laboratory as car-
bapenems were not routinely tested versus urinary tract iso-
lates. However, a prospective study initiated at our institution
following the identification of our first KPC-positive K. pneu-
moniae isolate showed that nearly 12% of the K. pneumoniae
strains recovered in our laboratory from all sources were pos-
itive for blaKPC. Most of these (64%) were urinary tract isolates
with evidence of both clonal expansion and the introduction of
unique, unrelated strains (data not shown). Currently, all of
the carbapenem-resistant Enterobacteriaceae recovered in our
laboratory are tested for the presence of blaKPC and of these,
99.0% contain blaKPC.
Our surveillance data indicate that blaKPC disseminates rap-
idly within a health care environment—primarily among
FIG. 1. KPC-specific PCR results generated from plasmid preparations of wild-type P. mirabilis (Pm), the TT host strain, and TT/pPmir. A
fragment of the size expected (892 bp) was generated from wild-type P. mirabilis and the host strain transformed with the P. mirabilis KPC plasmid
(pPmir) but not from the host strain.




P. mirabilisa TT onlyb TT/pPmirc
Meropenem 32 0.047 0.125 3
Ertapenem 32 0.006 0.023 4
Imipenem 32 0.38 1.5 4
Doripenem 32 0.047 0.125 3
a KPC (pPmir)-positive P. mirabilis.
b Carbapenem-susceptible E. coli host strain.
c E. coli host strain transformed with pPmir from P. mirabilis.
d Fold difference between MICs for host strain and transformant.
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strains of K. pneumoniae. However, we have also identified
KPC-positive isolates of Enterobacter cloacae, Citrobacter
freundii, Klebsiella oxytoca, and most recently, P. mirabilis. In
an effort to curb this trend, we have begun routine screening of
all gram-negative, carbapenem-resistant organisms for blaKPC
with a real-time PCR assay. If positive, results are conveyed to
infection prevention personnel for appropriate precautions.
Although the carbapenem MICs for transformed E. coli
FIG. 2. PCR and sequencing of pPmir and a subsequent BLAST search determined that the PCR fragment generated showed 100% homology
with the KPC-2 gene sequence submitted to GenBank.
FIG. 3. PCR and sequencing of pPmir and a subsequent BLAST search determined that the PCR fragment generated shared 100% identity
with the KPC-2 protein sequence submitted to GenBank.
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were considerably lower than those for the donor strain of P.
mirabilis, all were three- to fourfold higher than those for the
TT host recipient strain. While this finding was somewhat
perplexing, it was not extraordinary since similar results have
been reported by others (12, 18). Several possibilities exist to
explain this observation: (i) the promoter associated with
pPmir has low affinity for E. coli RNA polymerase, (ii) pPmir
has a much lower copy number in the E. coli host, and/or (iii)
the P. mirabilis donor strain has multiple mechanisms of car-
bapenem resistance, i.e., porin mutation or genetic determi-
nants that the E. coli host does not have. In terms of the latter,
we were unable to demonstrate the presence of a metallo--
lactamase with an EDTA disk approximation test (data not
shown).
In conclusion, we give here what we believe to be the first
description of a KPC-positive strain of P. mirabilis. Based on
this finding, it would be prudent to routinely screen all clini-
cally relevant isolates of Enterobacteriaceae for carbapenem
resistance—even under circumstances where the use of this
class of drug for the treatment of infection would be less likely,
i.e., uncomplicated urinary tract infection.
We thank Jennifer Bauer-Turpin for technical assistance with DNA
sequencing.
The mention of trade names or commercial products in this report
is solely for the purpose of providing specific information and does not
imply recommendation or endorsement by the U.S. Department of
Agriculture.
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